Log on/register
BioMed Central home | Journals A-Z | Feedback | Support | My details
 
Open AccessResearch

Characterization of the tumor marker muc16 (ca125) expressed by murine ovarian tumor cell lines and identification of a panel of cross-reactive monoclonal antibodies

Cara AR Goodell1 email, Jennifer A Belisle1 email, Jennifer AA Gubbels1 email, Martine Migneault2 email, Claudine Rancourt2 email, Joseph Connor1 email, Muthusamy Kunnimalaiyaan3 email, Rachel Kravitz4 email, Ward Tucker4 email, Michael Zwick5 email and Manish S Patankar1 email

Department of Obstetrics and Gynecology, University of Wisconsin-Madison, Madison, Wisconsin-53792, USA

Department of Microbiology and Infectiology, Universite de Sherbrooke, Sherbrooke, Canada

Department of Surgery, University of Wisconsin-Madison, Wisconsin-53792, USA

NeoClone Biotechnology, Madison, Wisconsin-53713, USA

AndroBioSys Inc, 73 High Street, Buffalo, New York 14203-1149, USA

author email corresponding author email

Journal of Ovarian Research 2009, 2:8doi:10.1186/1757-2215-2-8

Published: 18 June 2009

Abstract

Objectives

The ovarian tumor marker CA125 is expressed on human MUC16, a cell surface bound mucin that is also shed by proteolytic cleavage. Human MUC16 is overexpressed by ovarian cancer cells. MUC16 facilitates the binding of ovarian tumor cells to mesothelial cells lining the peritoneal cavity. Additionally, MUC16 also is a potent inhibitor of natural killer cell mediated anti-tumor cytotoxic responses. Extensive studies using human as well as murine ovarian tumor cell models are required to clearly define the function of MUC16 in the progression of ovarian tumors. The major objective of this study was to determine if the murine ovarian tumor cells, MOVCAR, express Muc16 and to characterize antibodies that recognize this mucin.

Methods

RT-PCR analysis was used for detecting the Muc16 message and size exclusion column chromatography for isolating Muc16 produced by MOVCAR cells. Soluble and cell-associated murine Muc16 were analyzed, respectively, by Western blotting and flow cytometry assays using a new panel of antibodies. The presence of N-linked oligosaccharides on murine Muc16 was determined by ConA chromatography.

Results

We demonstrate that murine Muc16 is expressed by mouse ovarian cancer cells as an ~250 kDa glycoprotein that carries both O-linked and N-linked oligosaccharides. In contrast to human MUC16, the murine ortholog is primarily released from the cells and cannot be detected on the cell surface. Since the released murine Muc16 is not detected by conventional anti-CA125 assays, we have for the first time identified a panel of anti-human MUC16 antibodies that also recognizes the murine counterpart.

Conclusion

The antibodies identified in this study can be used in future purification of murine Muc16 and exhaustive study of its properties. Furthermore, the initial identification and characterization of murine Muc16 is a vital preliminary step in the development of effective murine models of human ovarian cancer. These models will aid in the further elucidation of the role that human MUC16 plays in the etiology and progression of ovarian tumors.


© 1999-2010 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.